Common mistakes with steroids

An, Yoon‐Kyo

doi:10.1111/jgh.15458

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reduced synthesis of anti-inflammatory cytokines leads to remission in patients with active IBD. However, the medications are not recommended for long-term use due to severe side-effects ( 82 ), including peptic ulcers, cataracts, hypertension, adrenal atrophy, amenorrhea, type II diabetes, hyperglycemia, Cushing's syndrome, a high risk of infection, osteoporosis and avascular necrosis. According to the study by Lichtenstein et al ( 83 ), the use of steroids is associated with both progression and a risk of mortality in patients with IBD, when compared to immunomodulators and biological therapies.…”

Section: Chemoprophylaxismentioning

confidence: 99%

Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review)

Ogurchenok,

Khalin,

Bryukhovetskiy

2024

Med Int

View full text Add to dashboard Cite

The diagnostics of colorectal cancer (CRC) and precancerous lesions in the colon is one of the most urgent matters to be considered for the modern protocols of complex examination, recommended for use from the age of 45 years, and including both instrumental and laboratory methods of research: Colonoscopy, CT colonography, flexible sigmoidoscopy, fecal occult blood test, fecal immunohistochemistry test and stool DNA test Nevertheless, the removal of those precancerous lesions does not solve the issue, and, apart from the regular endoscopic monitoring of patients who are at a high risk of developing CRC, the pharmacological treatment of certain key pathogenic mechanisms leading to the development of CRC is required. The present review to discusses the function of β-catenin in the transformation of precancerous colorectal lesions into CRC, when collaborating with PI3K/AKT/mTOR signaling pathway and other mechanisms. The existing methods for the early diagnostics and prevention of discovered anomalies are described and categorized. The analysis of the approaches to chemoprophylaxis of CRC, depending on the results of endoscopic, morphological and molecular-genetic tests, is presented.

show abstract

Section: Chemoprophylaxismentioning

confidence: 99%

Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review)

Ogurchenok,

Khalin,

Bryukhovetskiy

2024

Med Int

View full text Add to dashboard Cite

show abstract

“…The reduced synthesis of proinflammatory cytokines helps in the induction of remission in patients with active IBD. However, their long-term treatment is not recommended due to significant adverse effects such as an increased risk of mortality, infection [51], osteoporosis, psychological disturbances including insomnia, schizophrenia, depression, and euphoria, moon face, fat deposition, dermatological disorders, steroid-induced diabetes [52] and a negative effect on growth in prepubescent children.…”

Section: Corticosteroidsmentioning

confidence: 99%

Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response

Elhag

Kumar

Saadaoui

et al. 2022

IJMS

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammation of the gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and remitting clinical course that necessitates lifelong monitoring and treatment. Although the availability of a variety of effective therapeutic options including immunomodulators and biologics (such as TNF, CAM inhibitors) has led to a paradigm shift in the treatment outcomes and clinical management of IBD patients, some patients still either fail to respond or lose their responsiveness to therapy over time. Therefore, according to the recent Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) recommendations, continuous disease monitoring from symptomatic relief to endoscopic healing along with short- and long-term therapeutic responses are critical for providing IBD patients with a tailored therapy algorithm. Moreover, considering the high unmet need for novel therapeutic approaches for IBD patients, various new modulators of cytokine signaling events (for example, JAK/TYK inhibitors), inhibitors of cytokines (for example IL-12/IL-23, IL-22, IL-36, and IL-6 inhibitors), anti-adhesion and migration strategies (for example, β7 integrin, sphingosine 1-phosphate receptors, and stem cells), as well as microbial-based therapeutics to decolonize the bed buds (for example, fecal microbiota transplantation and bacterial inhibitors) are currently being evaluated in different phases of controlled clinical trials. This review aims to offer a comprehensive overview of available treatment options and emerging therapeutic approaches for IBD patients. Furthermore, predictive biomarkers for monitoring the therapeutic response to different IBD therapies are also discussed.

show abstract

Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling

Jang,

Jeong

2023

BioChip J

View full text Add to dashboard Cite

Common mistakes with steroids

Cited by 3 publications

References 16 publications

Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review)

Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review)

Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response

Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling

Contact Info

Product

Resources

About